Bristol Entecavir Goes To Antiviral Advisory Committee March 11

The oral nucleoside analogue is pending at FDA for treatment of chronic hepatitis B infection and is receiving a priority review. Bristol's Phase III trials show statistically significant improvements compared to GlaxoSmithKline's Epivir-HBV.